Jacalyn Mara Rosenblatt, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Vaccines | 11 | 2016 | 1044 | 1.450 |
Why?
|
| Dendritic Cells | 12 | 2013 | 2753 | 1.260 |
Why?
|
| Multiple Myeloma | 10 | 2022 | 5193 | 0.630 |
Why?
|
| Cell Fusion | 7 | 2012 | 294 | 0.450 |
Why?
|
| Remission Induction | 2 | 2016 | 2408 | 0.430 |
Why?
|
| Immunotherapy | 7 | 2022 | 4728 | 0.430 |
Why?
|
| Antigens, CD | 2 | 2011 | 4022 | 0.340 |
Why?
|
| Granzymes | 1 | 2010 | 278 | 0.300 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2016 | 3623 | 0.300 |
Why?
|
| Lymphocyte Transfusion | 1 | 2008 | 232 | 0.290 |
Why?
|
| Antigens, Differentiation | 1 | 2010 | 919 | 0.280 |
Why?
|
| Vaccination | 2 | 2016 | 3433 | 0.270 |
Why?
|
| T-Lymphocytes | 5 | 2016 | 10269 | 0.270 |
Why?
|
| Mucin-1 | 5 | 2012 | 538 | 0.270 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 1147 | 0.260 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2011 | 1852 | 0.230 |
Why?
|
| Immunologic Factors | 2 | 2022 | 1600 | 0.200 |
Why?
|
| Transplantation, Autologous | 3 | 2013 | 2126 | 0.190 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2016 | 3105 | 0.160 |
Why?
|
| Immunity, Cellular | 3 | 2013 | 1559 | 0.150 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2008 | 1505 | 0.150 |
Why?
|
| Leukemia | 1 | 2006 | 1527 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2013 | 5708 | 0.140 |
Why?
|
| Cytokines | 2 | 2012 | 7440 | 0.140 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 3042 | 0.140 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2011 | 1352 | 0.140 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2011 | 3198 | 0.130 |
Why?
|
| Vitamin D | 1 | 2010 | 3311 | 0.130 |
Why?
|
| HMGB1 Protein | 1 | 2017 | 141 | 0.130 |
Why?
|
| Lymphocyte Activation | 6 | 2012 | 5490 | 0.120 |
Why?
|
| Th1-Th2 Balance | 2 | 2012 | 38 | 0.120 |
Why?
|
| Chemokine CXCL12 | 1 | 2017 | 457 | 0.120 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2012 | 1786 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 4299 | 0.120 |
Why?
|
| Anilides | 1 | 2017 | 415 | 0.110 |
Why?
|
| Dexamethasone | 1 | 2021 | 1965 | 0.110 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2008 | 687 | 0.110 |
Why?
|
| Antigen Presentation | 2 | 2010 | 1247 | 0.100 |
Why?
|
| Clodronic Acid | 1 | 2011 | 60 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 11844 | 0.100 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 1014 | 0.090 |
Why?
|
| Immune System | 1 | 2016 | 801 | 0.090 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2012 | 133 | 0.090 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2012 | 338 | 0.090 |
Why?
|
| Cell Proliferation | 6 | 2017 | 10490 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 1119 | 0.090 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2010 | 70 | 0.090 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2011 | 355 | 0.080 |
Why?
|
| Osteolysis | 1 | 2011 | 274 | 0.080 |
Why?
|
| Mitogens | 1 | 2010 | 229 | 0.080 |
Why?
|
| Antibodies, Protozoan | 1 | 2010 | 253 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2016 | 2003 | 0.080 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 316 | 0.080 |
Why?
|
| Interleukin-12 | 2 | 2008 | 578 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2012 | 4613 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2011 | 909 | 0.070 |
Why?
|
| Thalidomide | 1 | 2012 | 885 | 0.070 |
Why?
|
| Diphosphonates | 1 | 2011 | 635 | 0.070 |
Why?
|
| Cell Polarity | 1 | 2010 | 639 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 2964 | 0.070 |
Why?
|
| Clone Cells | 1 | 2010 | 1672 | 0.070 |
Why?
|
| Th17 Cells | 1 | 2012 | 798 | 0.060 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2007 | 430 | 0.060 |
Why?
|
| Imidazoles | 1 | 2011 | 1174 | 0.060 |
Why?
|
| Oligonucleotides | 1 | 2008 | 564 | 0.060 |
Why?
|
| Pyridines | 1 | 2017 | 2888 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2010 | 1868 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 895 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2011 | 1892 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 2006 | 605 | 0.060 |
Why?
|
| Bone Density Conservation Agents | 1 | 2011 | 797 | 0.060 |
Why?
|
| Humans | 24 | 2022 | 768369 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2010 | 3164 | 0.060 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 2150 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2016 | 65408 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2011 | 5893 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 9425 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 13709 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 3710 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2012 | 4403 | 0.050 |
Why?
|
| Neoplasms | 2 | 2012 | 22389 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 4931 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2012 | 19035 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 1357 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 637 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 1602 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 4834 | 0.040 |
Why?
|
| Aged | 5 | 2021 | 171514 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 890 | 0.040 |
Why?
|
| Adult | 6 | 2021 | 223528 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 2819 | 0.040 |
Why?
|
| Middle Aged | 5 | 2021 | 223406 | 0.040 |
Why?
|
| Receptors, CCR7 | 2 | 2008 | 106 | 0.030 |
Why?
|
| Male | 8 | 2021 | 364761 | 0.030 |
Why?
|
| Benzylamines | 1 | 2017 | 252 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 2017 | 245 | 0.030 |
Why?
|
| Female | 8 | 2021 | 396926 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 11206 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 5808 | 0.030 |
Why?
|
| Fowlpox virus | 1 | 2012 | 21 | 0.030 |
Why?
|
| JC Virus | 1 | 2012 | 87 | 0.020 |
Why?
|
| STAT Transcription Factors | 1 | 2012 | 190 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 152 | 0.020 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 17149 | 0.020 |
Why?
|
| Interleukin-10 | 2 | 2008 | 1184 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 307 | 0.020 |
Why?
|
| Reflex | 1 | 1992 | 374 | 0.020 |
Why?
|
| Ovulation Induction | 1 | 1992 | 277 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2011 | 262 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 903 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 1650 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 664 | 0.020 |
Why?
|
| Uterus | 1 | 1992 | 660 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2008 | 12176 | 0.020 |
Why?
|
| Arsenicals | 1 | 2008 | 117 | 0.020 |
Why?
|
| Recurrence | 2 | 2011 | 8510 | 0.020 |
Why?
|
| Cell Differentiation | 3 | 2011 | 11674 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 2228 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 1622 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2010 | 23639 | 0.020 |
Why?
|
| Oxides | 1 | 2008 | 403 | 0.020 |
Why?
|
| K562 Cells | 1 | 2007 | 645 | 0.020 |
Why?
|
| Animals | 5 | 2017 | 169424 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2011 | 1193 | 0.020 |
Why?
|
| Disease Progression | 1 | 2022 | 13643 | 0.020 |
Why?
|
| Hybrid Cells | 1 | 2005 | 421 | 0.020 |
Why?
|
| Glutathione | 1 | 2007 | 587 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2005 | 317 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 1625 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 751 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2005 | 510 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 2232 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2017 | 3076 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2008 | 1343 | 0.010 |
Why?
|
| Neutrophils | 1 | 2017 | 3790 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 1813 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 3790 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 3939 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2011 | 4040 | 0.010 |
Why?
|
| Cesarean Section | 1 | 1992 | 1414 | 0.010 |
Why?
|
| Apoptosis | 2 | 2011 | 9526 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 656 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2012 | 3417 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2005 | 655 | 0.010 |
Why?
|
| Phenotype | 2 | 2011 | 16712 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2007 | 1502 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 6856 | 0.010 |
Why?
|
| Cell Survival | 1 | 2011 | 5800 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 21157 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4582 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 5709 | 0.010 |
Why?
|
| Antibodies | 1 | 2008 | 2426 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2011 | 3145 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 13447 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 39429 | 0.010 |
Why?
|
| Regeneration | 1 | 2008 | 1527 | 0.010 |
Why?
|
| Lymphoma | 1 | 2007 | 1907 | 0.010 |
Why?
|
| Mice | 2 | 2017 | 82051 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 9376 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2008 | 3408 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 8051 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 22286 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 7449 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 15610 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 8636 | 0.010 |
Why?
|
| Afferent Pathways | 1 | 1992 | 304 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 22365 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 59679 | 0.000 |
Why?
|
| HIV Infections | 1 | 2012 | 17492 | 0.000 |
Why?
|
| Young Adult | 1 | 2012 | 60038 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1992 | 8201 | 0.000 |
Why?
|
| Rats | 1 | 1992 | 23839 | 0.000 |
Why?
|
| Pregnancy | 1 | 1992 | 30179 | 0.000 |
Why?
|